Combining Powdose® And Diffucaps® For Precise Solid Oral Dosing

As the shift toward personalized medicine accelerates, innovative technologies like POWDOSE® and Diffucaps® are enabling safer, more effective, and precisely tailored treatments. POWDOSE®, developed by AbbatiaLabs SA, is a customizable dosing device that allows users to set and dispense exact amounts of solid oral medications through a simple two-step mechanism. This user-friendly system reduces dosing errors and supports individualized therapy, particularly beneficial in pediatrics, chronic conditions, and diseases requiring dose titration.

Adare Pharma Solutions’ Diffucaps® technology complements POWDOSE by offering advanced multiparticulate formulations that enhance solubility, control drug release, and improve absorption in targeted areas of the gastrointestinal tract. These capabilities help minimize side effects and food interactions while ensuring more predictable therapeutic outcomes.

A recent study assessed the compatibility of these technologies by testing POWDOSE with Diffucaps granules (non-API). Four different POWDOSE devices, each delivering a defined fraction of the total dose (25%, 50%, 75%, 100%), were evaluated across 1,200 doses. Results showed excellent consistency and precision throughout the device's lifecycle, with no loss of accuracy regardless of reservoir fill level or dose size.

Together, POWDOSE and Diffucaps offer a highly effective platform for delivering personalized solid oral medications. The combination supports accurate self-administration, enhances therapeutic outcomes, and provides formulation teams with tools for tailored drug development. As medicine continues to trend toward individualized care, this dual-technology approach represents a powerful advancement in precision dosing and patient-centric pharmaceutical innovation.